Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Emu et al. 2018 NEJM 379: 645-654 published the results of ibalizumab to patients with with multidrugresistant (MDR) HIV-1 infection in whom multiple antiretroviral therapies had failed from a single-group, open-label, phase III trial with 40 subjects.
The authors' conclusion was: In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-week study. Evidence of the emergence of diminished ibalizumab susceptibility was observed in vitro in patients who had virologic failure.
Emu et al. 2018 NEJM 379: 645-654
…